AZD4573 for Relapsed/Refractory Classical Hodgkins Lymphoma

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Relapsed/Refractory Classical Hodgkins Lymphoma+5 More
AZD4573 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug, AZD4573, to see if it works well against two types of cancer, PTCL and cHL. The first part of the study will test how well the drug works and what side effects it has. If the drug looks promising, a second part of the study will test it in more people.

Eligible Conditions
  • Relapsed/Refractory Classical Hodgkins Lymphoma
  • Peripheral T-Cell Lymphoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Relapsed/Refractory Classical Hodgkins Lymphoma

Study Objectives

1 Primary · 11 Secondary · Reporting Duration: Cycle 1 (Cycle length is 35 days), Day 1 of Weeks 1-3 and Cycle 2 (Cycle length is 21 Days), Day 1 and Day 2

Week 1
Area under plasma concentration time curve from zero to infinity (AUC0-inf) of AZD4573
Area under the concentration-time curve from time zero to the last measurable concentration (AUC0-t) of AZD4573
Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast) of AZD4573
Half-life (t1/2) of AZD4573
Maximum observed plasma (peak) drug concentration (Cmax) of AZD4573
Time to reach peak or maximum observed concentration or response following drug administration (tmax) of AZD4573
Year 2
Frequency of Adverse events (AE) and Serious AEs (SAE)
Month 6
Complete response (CR) rate
Duration of response (DoR)
Objective Response Rate (ORR)
Overall survival (OS)
Progression-free survival (PFS)

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Relapsed/Refractory Classical Hodgkins Lymphoma

Trial Design

3 Treatment Groups

Cohort 1: non-natural killer (NK) PTCL (Non-NK PTCL)
1 of 3
Cohort 3: cHL
1 of 3
Cohort 2: NK PTCL
1 of 3
Experimental Treatment

81 Total Participants · 3 Treatment Groups

Primary Treatment: AZD4573 · No Placebo Group · Phase 2

Cohort 1: non-natural killer (NK) PTCL (Non-NK PTCL)
Drug
Experimental Group · 1 Intervention: AZD4573 · Intervention Types: Drug
Cohort 3: cHL
Drug
Experimental Group · 1 Intervention: AZD4573 · Intervention Types: Drug
Cohort 2: NK PTCL
Drug
Experimental Group · 1 Intervention: AZD4573 · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AZD4573
2017
Completed Phase 1
~50

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: cycle 1 (cycle length is 35 days), day 1 of weeks 1-3 and cycle 2 (cycle length is 21 days), day 1 and day 2

Who is running the clinical trial?

AstraZenecaLead Sponsor
3,956 Previous Clinical Trials
91,808,780 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have peripheral T-cell lymphoma.
You are willing and able to participate in all required evaluations and procedures in this study protocol including receiving IV administration of study drug and being admitted, if required, for at least 24 hours during study drug administration.
You have additional criteria for inclusion in the study.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 14th, 2021

Last Reviewed: October 23rd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.